What Physicians Want: Less of Promotional Content

Spain Reps Tick Right Boxes

Healthcare professionals are inundated by product-related promotional content from pharma firms and want less of that but more on areas such as safety, efficacy and real-world evidence, a new survey on engaging digitally-savvy physicians indicates. Spain emerges as a stand-out market where pharma appears to have fared relatively well in mapping physician preferences to their marketing activities.

Doctor webinar
Pharma Needs To Engage With HCPs More Efficiently • Source: Alamy

Healthcare Professionals (HCP)s may have turned more digitally savvy than ever amid the pandemic but pharma hasn’t quite delivered the goods so far in terms of effective or customer-centric engagement with physicians, a new global survey by Indegene, a global provider of healthcare solutions to the industry, indicates.

The study, which covered 984 physicians across the US, Europe, India and China, revealed that 70% of HCPs felt that pharma companies' sales reps do not completely understand their needs and expectations; additionally

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

More from Scrip